Healthcare entity
All 2 tracked stories fall under one category: market-trends. Eli Lilly is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 20-day window averages about 0.7 stories each week. Source depth averages 3.5 original sources per story, versus 3.1 across the same-window beat baseline.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: market-trends. Eli Lilly is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 20-day window averages about 0.7 stories each week. Source depth averages 3.5 original sources per story, versus 3.1 across the same-window beat baseline. At 6.5, the average consequence score sits above the same-window beat average of 6. orforglipron appears in 2 tracked Healthcare stories published from March 4, 2026 through March 23, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 441 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering orforglipron. Shared-story counts are live from our verified record — not editorial picks.
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Source: Adria Cimino (us) · fool.com
Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions.
Source: Prosper Junior Bakiny (us) · Keithen Drury (us)
orforglipron is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
